48 related articles for article (PubMed ID: 38725021)
1. TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination.
Liu H; Wang H; Zhang H; Yu M; Tang Y
Cancer Cell Int; 2024 Jun; 24(1):207. PubMed ID: 38867223
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 intrinsically promotes the proliferation of breast cancer cells through the SKP2-p27/p21 axis.
Elfoly M; Mirza JY; Alaiya A; Al-Hazzani AA; Tulbah A; Al-Alwan M; Ghebeh H
Cancer Cell Int; 2024 May; 24(1):161. PubMed ID: 38725021
[TBL] [Abstract][Full Text] [Related]
3. Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues.
Ghebeh H; Mansour FA; Colak D; Alfuraydi AA; Al-Thubiti AA; Monies D; Al-Alwan M; Al-Tweigeri T; Tulbah A
Antibodies (Basel); 2021 Jun; 10(3):. PubMed ID: 34206205
[TBL] [Abstract][Full Text] [Related]
4. Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics.
Xiao W; Zhang G; Chen B; Chen X; Wen L; Lai J; Li X; Li M; Liu H; Liu J; Han-Zhang H; Lizaso A; Liao N
J Cancer; 2021; 12(14):4408-4417. PubMed ID: 34093841
[No Abstract] [Full Text] [Related]
5. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
[TBL] [Abstract][Full Text] [Related]
7. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Du W; Zhu J; Zeng Y; Liu T; Zhang Y; Cai T; Fu Y; Zhang W; Zhang R; Liu Z; Huang JA
Cell Death Differ; 2021 Apr; 28(4):1284-1300. PubMed ID: 33139930
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
[TBL] [Abstract][Full Text] [Related]
9. Regulation of sister chromatid cohesion by nuclear PD-L1.
Yu J; Qin B; Moyer AM; Nowsheen S; Tu X; Dong H; Boughey JC; Goetz MP; Weinshilboum R; Lou Z; Wang L
Cell Res; 2020 Jul; 30(7):590-601. PubMed ID: 32350394
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis.
Mansour FA; Al-Mazrou A; Al-Mohanna F; Al-Alwan M; Ghebeh H
Oncoimmunology; 2020; 9(1):1729299. PubMed ID: 32313717
[TBL] [Abstract][Full Text] [Related]
11. The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling.
Chen RQ; Xu XH; Liu F; Li CY; Li YJ; Li XR; Jiang GY; Hu F; Liu D; Pan F; Qiu XY; Chen XQ
Front Oncol; 2019; 9():1347. PubMed ID: 31850228
[TBL] [Abstract][Full Text] [Related]
12. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
[TBL] [Abstract][Full Text] [Related]
13. Cancer statistics, 2019.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2019 Jan; 69(1):7-34. PubMed ID: 30620402
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors: recent progress and potential biomarkers.
Darvin P; Toor SM; Sasidharan Nair V; Elkord E
Exp Mol Med; 2018 Dec; 50(12):1-11. PubMed ID: 30546008
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
Dong P; Xiong Y; Yue J; Hanley SJB; Watari H
Front Oncol; 2018; 8():386. PubMed ID: 30283733
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.
Gupta HB; Clark CA; Yuan B; Sareddy G; Pandeswara S; Padron AS; Hurez V; Conejo-Garcia J; Vadlamudi R; Li R; Curiel TJ
Signal Transduct Target Ther; 2016; 1():16030-. PubMed ID: 28798885
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H
Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
